Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Thinking Big, Thinking Small

Philip Seo, MD, MHS  |  Issue: June 2019  |  

Philip Seo, MD, MHSPhilip Seo, MD, MHS, is an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore. He is director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Hoffman GS, Stone JH. Foreword. Special Issue: Proceedings of the 14th International Vasculitis and ANCA Workshop. APMIS 2009;117:1.
  2. Vasculitis 2019: International Vasculitis & ANCA Workshop.
  3. Yeung RSM. Towards precision medicine—Lessons learned from Kawasaki Disease. The 19th International Vasculitis and ANCA Workshop: Philadelphia. 2019 Apr 9.
  4. Burns JC, Kushner HI, Bastian JF, et al. Kawasaki disease: A brief history. Pediatrics. 2000;106(2):E27.
  5. Tanaka K, Onouchi Z, Tomisawa M, et al. A study of Kawasaki disease: Presentation of an autopsy case and relationship with infantile periarteritis nodosa [in Japanese]. Nippon Shonika Gakkai Zasshi (J Jpn Pediatr Soc). 1973;77:397–411.
  6. Quote investigator.
  7. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004 Aug 7–13;364(9433):533–544.
  8. Rodó X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152.
  9. Eisenstadt L. After a decade of genome-wide association studies, a new phase of discovery pushes on. Broad Institute. 2017 Aug 14.
  10. Burgner D, Davila S, Breunis WB, et al. A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki’s disease. PLoS Genet. 2009 Jan;5(1):e1000319.

Related Articles
    Dr. Kawasaki

    Tomisaku Kawasaki, Pediatrician Who Discovered Disease That Bears His Name, Dies at 95

    Japanese pediatrician Tomisaku Kawasaki, MD, who identified an inflammatory syndrome that affects children, died on June 5 in Tokyo. He was 95. Tenacity & Attention to Detail Born Feb. 7, 1925, in Tokyo, Dr. Kawasaki graduated from medical school at what is now Chiba University in Chiba, Japan, in 1948 and worked as staff pediatrician…

    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    Exploring Kawasaki Disease

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…